CBO Says CREATES Act Would Save Over $3 Billion

The Congressional Budget Office (CBO) estimates bipartisan legislation designed to speed generic drugs to market could save the federal government as much as $3.3 billion.

The CREATES Act — which would create a pathway for generic drugmakers to sue branded manufacturers for withholding samples necessary for generic development — could reduce direct federal drug spending by $3.3 billion and quicken market entry for generics and biosimilars by up to two years.

 “The CBO score validates what AAM and our member companies have been saying for years: that CREATES will reduce drug prices and increase access to medicines for patients who need it most,” said Rachel Schwartz, a spokesperson for the Association for Accessible Medicines. “After years of discussion and deliberation, it’s time to pass CREATES.”